Huiqiang Huang

机构：Sun Yat-sen University, Roche (Canada), First Affiliated Hospital of Guangzhou Medical University, Sun Yat-sen University Cancer Center, Guangzhou Medical University · ORCID：0000-0001-7500-8056

发表论文 73 篇 · 总被引 963 次 · h-index 19

代表论文

• First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial (2024 · The Lancet Haematology · 被引 33)
• Single‐Cell Analysis Reveals Malignant Cells Reshape the Cellular Landscape and Foster an Immunosuppressive Microenvironment of Extranodal NK/T‐Cell Lymphoma (2023 · Advanced Science · 被引 30)
• Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study (2023 · Blood Advances · 被引 20)
• Heat shock factor 1 promotes proliferation and chemoresistance in diffuse large B-cell lymphoma by enhancing the cell cycle and DNA repair (2025 · Cell Death and Disease · 被引 6)
• Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Clinical Trial (2023 · Blood · 被引 6)
• Chidamide, a Histone Deacetylase Inhibitor, Combined With R‐ GemOx in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma ( TRUST ): A Multicenter, Single‐Arm, Phase 2 Trial (2025 · Cancer Medicine · 被引 5)